Alkermes
tumor targeted split advancing toward preclinical proof of concept and cell line development engineer tumor targeted subunits fused to proprietary tumor targeting antibody demonstrate that tumor targeted subunits are retained in tumors with expected kinetics demonstrate that sequentially administered subunits combine to form functional and drive dose dependent production in humanized mice complete humanization of tumor targeting antibodies ongoing characterize lead candidates and preclinical proof of concept studies planned initiate cell line development | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
109 of 144
Related slides by other companies
Berkeley Lights
IPO
July 2020
cell line development an | Berkeley Lights
Cytek
Investor Day
June 2022
mapping the landscape of the lung in pneumococcal pneumonia nature antigen presentation by epithelial cell function and regulates barrier immunity i | Cytek
Absci
Investor Presentation
March 2023
specialized coli cell lines | Absci
AbCellera
Investor Conference
September 2021
forward integration to accelerate drug development | AbCellera
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io